BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20615140)

  • 21. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
    Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
    Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.
    Celetti A; Cerrato A; Merolla F; Vitagliano D; Vecchio G; Grieco M
    Oncogene; 2004 Jan; 23(1):109-21. PubMed ID: 14712216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma.
    Ciampi R; Giordano TJ; Wikenheiser-Brokamp K; Koenig RJ; Nikiforov YE
    Endocr Relat Cancer; 2007 Jun; 14(2):445-52. PubMed ID: 17639057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporal trends and clinical correlates for the ret/PTC1 mutation in papillary thyroid carcinoma.
    Burgess JR; Skabo S; McArdle K; Tucker P
    ANZ J Surg; 2003; 73(1-2):31-5. PubMed ID: 12534735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.
    Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R
    Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).
    Nakazawa T; Kondo T; Kobayashi Y; Takamura N; Murata S; Kameyama K; Muramatsu A; Ito K; Kobayashi M; Katoh R
    Cancer; 2005 Sep; 104(5):943-51. PubMed ID: 16015630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rearrangement analysis in archival thyroid tissues: punching microdissection and artificial RET/PTC 1-12 transcripts.
    Imkamp F; von Wasielewski R; Musholt TJ; Musholt PB
    J Surg Res; 2007 Dec; 143(2):350-63. PubMed ID: 17655865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RET oncogene expression of papillary thyroid carcinoma in Korea.
    Chung KW; Chang MC; Noh DY; Oh SK; Choe KJ; Youn YK
    Surg Today; 2004; 34(6):485-92. PubMed ID: 15170542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression.
    Knostman KA; Venkateswaran A; Zimmerman B; Capen CC; Jhiang SM
    Thyroid; 2007 Dec; 17(12):1181-8. PubMed ID: 18004977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent overexpression of RET/PTC1 and TTF1 confers tumorigenicity to thyrocytes.
    Endo T; Kobayashi T
    Endocr Relat Cancer; 2013 Dec; 20(6):767-76. PubMed ID: 24014739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma.
    de Martimprey H; Bertrand JR; Fusco A; Santoro M; Couvreur P; Vauthier C; Malvy C
    Nucleic Acids Res; 2008 Jan; 36(1):e2. PubMed ID: 18079153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic Limitation of Fine-Needle Aspiration (FNA) on Indeterminate Thyroid Nodules Can Be Partially Overcome by Preoperative Molecular Analysis: Assessment of RET/PTC1 Rearrangement in BRAF and RAS Wild-Type Routine Air-Dried FNA Specimens.
    Ko YS; Hwang TS; Kim JY; Choi YL; Lee SE; Han HS; Kim WS; Kim SK; Park KS
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.
    Sheils OM; O'Leary JJ; Sweeney EC
    J Pathol; 2000 Sep; 192(1):32-6. PubMed ID: 10951397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model.
    Cahill S; Smyth P; Finn SP; Denning K; Flavin R; O'Regan EM; Li J; Potratz A; Guenther SM; Henfrey R; O'Leary JJ; Sheils O
    Mol Cancer; 2006 Dec; 5():70. PubMed ID: 17156473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RET/PTC rearrangement occurring in primary peritoneal carcinoma.
    Flavin R; Jackl G; Finn S; Smyth P; Ring M; O'Regan E; Cahill S; Unger K; Denning K; Jinghuan Li ; Aherne S; Tallini G; Gaffney E; O'Leary JJ; Zitzelsberger H; Sheils O
    Int J Surg Pathol; 2009 Jun; 17(3):187-97. PubMed ID: 19147513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.
    Borrello MG; Alberti L; Fischer A; Degl'innocenti D; Ferrario C; Gariboldi M; Marchesi F; Allavena P; Greco A; Collini P; Pilotti S; Cassinelli G; Bressan P; Fugazzola L; Mantovani A; Pierotti MA
    Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14825-30. PubMed ID: 16203990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.